Cumberland Pharmaceuticals Inc
CPIX4.410USD
+0.030+0.68%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
65.96MMarket Cap
LossP/E TTM
More Details of Cumberland Pharmaceuticals Inc Company
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Cumberland Pharmaceuticals Inc Info
Ticker SymbolCPIX
Company nameCumberland Pharmaceuticals Inc
IPO dateAug 11, 2009
CEOKazimi (A. J)
Number of employees91
Security typeOrdinary Share
Fiscal year-endAug 11
Address1600 West End Avenue, Suite 1300
CityNASHVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code37203
Phone18774842700
Websitehttps://www.cumberlandpharma.com/
Ticker SymbolCPIX
IPO dateAug 11, 2009
CEOKazimi (A. J)
Company Executives of Cumberland Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
294.62K
+0.69%
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
44.79K
+0.68%
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
33.24K
+0.23%
Mr. John M. Hamm
Mr. John M. Hamm
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
20.07K
-22.81%
Mr. Todd M. Anthony
Mr. Todd M. Anthony
Vice President - Organizational Development
Vice President - Organizational Development
19.33K
+18.37%
Mr. Chris T. Bitterman
Mr. Chris T. Bitterman
Vice President - Sales and Marketing
Vice President - Sales and Marketing
6.68K
+42.71%
Mr. Martin S. Brown, Jr.
Mr. Martin S. Brown, Jr.
Director
Director
--
--
Dr. Gordon R. Bernard, M.D.
Dr. Gordon R. Bernard, M.D.
Independent Director
Independent Director
--
--
Mr. A. J. Kazimi
Mr. A. J. Kazimi
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Joseph C. Galante
Mr. Joseph C. Galante
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth J. Krogulski
Mr. Kenneth J. Krogulski
Independent Director
Independent Director
294.62K
+0.69%
Mr. James R. Jones
Mr. James R. Jones
Independent Director
Independent Director
44.79K
+0.68%
Ms. Caroline R. Young
Ms. Caroline R. Young
Independent Director
Independent Director
33.24K
+0.23%
Mr. John M. Hamm
Mr. John M. Hamm
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
20.07K
-22.81%
Mr. Todd M. Anthony
Mr. Todd M. Anthony
Vice President - Organizational Development
Vice President - Organizational Development
19.33K
+18.37%
Mr. Chris T. Bitterman
Mr. Chris T. Bitterman
Vice President - Sales and Marketing
Vice President - Sales and Marketing
6.68K
+42.71%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Sancuso
3.12M
28.78%
Kristalose
2.75M
25.41%
Vibativ
2.70M
24.93%
Caldolor
1.59M
14.66%
Other
492.39K
4.54%
Other
181.42K
1.67%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Sancuso
3.12M
28.78%
Kristalose
2.75M
25.41%
Vibativ
2.70M
24.93%
Caldolor
1.59M
14.66%
Other
492.39K
4.54%
Other
181.42K
1.67%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Kazimi (A J)
38.12%
Millennium Management LLC
4.00%
Ikarian Capital LLC
3.72%
Renaissance Technologies LLC
3.45%
The Vanguard Group, Inc.
2.75%
Other
47.96%
Shareholders
Shareholders
Proportion
Kazimi (A J)
38.12%
Millennium Management LLC
4.00%
Ikarian Capital LLC
3.72%
Renaissance Technologies LLC
3.45%
The Vanguard Group, Inc.
2.75%
Other
47.96%
Shareholder Types
Shareholders
Proportion
Individual Investor
41.64%
Hedge Fund
13.09%
Investment Advisor/Hedge Fund
4.95%
Investment Advisor
4.76%
Venture Capital
0.07%
Research Firm
0.06%
Other
35.43%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
58
3.43M
28.11%
--
2025Q3
58
3.43M
28.11%
-275.21K
2025Q2
56
3.70M
29.59%
-598.10K
2025Q1
49
4.30M
21.56%
+1.08M
2024Q4
42
1.86M
15.86%
-201.77K
2024Q3
41
2.06M
16.04%
-33.69K
2024Q2
41
2.10M
18.07%
-86.66K
2024Q1
46
2.18M
18.49%
-434.68K
2023Q4
49
2.22M
18.85%
-9.15K
2023Q3
52
2.23M
19.44%
-191.47K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Kazimi (A J)
5.70M
38.1%
+254.00
+0.00%
Sep 30, 2025
Millennium Management LLC
775.98K
5.19%
-33.92K
-4.19%
Jun 30, 2025
Ikarian Capital LLC
595.93K
3.98%
-144.07K
-19.47%
Jun 30, 2025
Renaissance Technologies LLC
494.96K
3.31%
-8.40K
-1.67%
Jun 30, 2025
The Vanguard Group, Inc.
411.79K
2.75%
-4.78K
-1.15%
Jun 30, 2025
Krogulski (Kenneth J)
291.03K
1.95%
+1.31K
+0.45%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
252.89K
1.69%
+700.00
+0.28%
Jun 30, 2025
J. Goldman & Co., L.P.
220.71K
1.48%
-20.77K
-8.60%
Jun 30, 2025
Bridgeway Capital Management, LLC
188.35K
1.26%
+4.20K
+2.28%
Jun 30, 2025
Boothbay Fund Management, LLC
180.23K
1.2%
-43.57K
-19.47%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cumberland Pharmaceuticals Inc?
The top five shareholders of Cumberland Pharmaceuticals Inc are:
Kazimi (A J) holds 5.70M shares, accounting for 38.10% of the total shares.
Millennium Management LLC holds 775.98K shares, accounting for 5.19% of the total shares.
Ikarian Capital LLC holds 595.93K shares, accounting for 3.98% of the total shares.
Renaissance Technologies LLC holds 494.96K shares, accounting for 3.31% of the total shares.
The Vanguard Group, Inc. holds 411.79K shares, accounting for 2.75% of the total shares.
Kazimi (A J) holds 5.70M shares, accounting for 38.10% of the total shares.
Millennium Management LLC holds 775.98K shares, accounting for 5.19% of the total shares.
Ikarian Capital LLC holds 595.93K shares, accounting for 3.98% of the total shares.
Renaissance Technologies LLC holds 494.96K shares, accounting for 3.31% of the total shares.
The Vanguard Group, Inc. holds 411.79K shares, accounting for 2.75% of the total shares.
What are the top three shareholder types of Cumberland Pharmaceuticals Inc?
The top three shareholder types of Cumberland Pharmaceuticals Inc are:
Kazimi (A J)
Millennium Management LLC
Ikarian Capital LLC
Kazimi (A J)
Millennium Management LLC
Ikarian Capital LLC
How many institutions hold shares of Cumberland Pharmaceuticals Inc (CPIX)?
As of 2025Q4, 58 institutions hold shares of Cumberland Pharmaceuticals Inc, with a combined market value of approximately 3.43M, accounting for 28.11% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Cumberland Pharmaceuticals Inc?
In FY2025Q2, the Sancuso business generated the highest revenue for Cumberland Pharmaceuticals Inc, amounting to 3.12M and accounting for 28.78% of total revenue.
